ODTX on Nasdaq

Odyssey Therapeutics, Inc.

American biological products company based in Boston, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerODTX on Nasdaq
IndustryBiological Products, (No Diagnostic Substances)
HeadquartersDE
Incorporated inDE²
Business address51 Sleeper Street, Boston, Ma 02210²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Leadership

Who has led Odyssey Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

Jason Haas2026–now

Chief financial officerJason Haas May 7, 2026 to now³

Board members and other officers (14)

OfficerAnthony W. Opipari May 7, 2026 to now⁴
OfficerCollin M. Todd May 7, 2026 to now⁵
OfficerGary D. Glick May 7, 2026 to now⁶
OfficerJolie Siegel May 7, 2026 to now⁷
OfficerNatalie Dales May 7, 2026 to now⁸
Board memberAranicki Ksenija Pavletic May 7, 2026 to now⁹
Board memberCarolyn Ng May 7, 2026 to now¹⁰
Board memberGary D. Glick May 7, 2026 to now⁶
Board memberIan F. Smith May 7, 2026 to now¹¹
Board memberJeffrey Leiden May 7, 2026 to now¹²
Board memberOurania Tatsis May 7, 2026 to now¹³
Board memberShelley Chu May 7, 2026 to now¹⁴
Board memberTimothy P. Walbert May 7, 2026 to now¹⁵
Board memberValerie Odegard May 7, 2026 to now¹⁶

Filings

68 filings to the SEC since October 2021: 2 quarterly reports, 5 major events, 34 insider forms, 6 large holders, 5 private raises, 16 other. The latest 20:

Sep 9, 20268-K EDGAR
Aug 6, 202610-Q EDGAR
Aug 4, 20268-K EDGAR
Jun 23, 20268-K EDGAR
Jun 17, 20268-K EDGAR
Jun 17, 202610-Q EDGAR
Jun 5, 2026SCHEDULE 13G EDGAR
May 18, 2026SCHEDULE 13G EDGAR
May 18, 2026SCHEDULE 13D EDGAR
May 18, 2026SCHEDULE 13D EDGAR
May 15, 2026SCHEDULE 13D EDGAR
May 15, 2026SCHEDULE 13D EDGAR
May 13, 20264 EDGAR
May 12, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
May 12, 20263 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
May 11, 20264 EDGAR
May 11, 20264 EDGAR
May 11, 20264 EDGAR
May 11, 20264 EDGAR
May 11, 20264 EDGAR

The 68 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 6 such filings since October 2021:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Jun 16, 2025Raised $214 million in a private offering of equity Form D: 55 investors so far Form D
Oct 25, 2023Raised $117.2 million in a private offering of equity Form D: $121.1 million offered in all Form D
May 13, 2022Raised $168 million in a private offering of equity Form D: $174.9 million offered in all Form D
Aug 30, 2021Raised $91.6 million in a private offering of equity Form D: 63 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 58. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Fmr LLC	5,179,262	$96.9M	0.0%	New
SR One Capital Management, LP	3,794,883	$71.0M	6.8%	New
Tpg Gp A, LLC	3,690,146	$69.0M	1.4%	New
Lightspeed Management Company, L.l.c.	3,608,443	$67.5M	2.8%	New
Orbimed Advisors LLC	3,001,198	$56.2M	1.1%	New
Sanofi	1,991,918	$37.3M	7.0%	New
Deerfield Management Company, L.P.	1,046,139	$19.6M	0.2%	New
Sands Capital Alternatives, LLC	875,000	$16.4M	2.7%	New
Hhlr Advisors, Ltd.	831,656	$15.6M	1.9%	New
General Catalyst Group Management, LLC	810,272	$15.2M	8.0%	New
Affinity Asset Advisors, LLC	766,346	$14.3M	0.7%	New
Adage Capital Partners Gp, L.l.c.	725,000	$13.6M	0.0%	New
Vanguard Capital Management LLC	720,440	$13.5M	0.0%	New
Foresite Capital Management V, LLC	713,105	$13.3M	3.7%	New
Vivo Capital, LLC	575,000	$10.8M	1.0%	New
EcoR1 Capital, LLC	555,555	$10.4M	0.5%	New
Logos Global Management LP	521,736	$9.8M	0.4%	New
Marshall Wace, Llp	492,697	$9.2M	0.0%	New
Catalio Capital Management, LP	457,839	$8.6M	1.6%	New
Redmile Group, LLC	425,000	$8.0M	0.5%	New
Balyasny Asset Management L.P.	393,862	$7.4M	0.0%	New
Woodline Partners LP	345,746	$6.5M	0.0%	New
Franklin Resources Inc	275,022	$5.1M	0.0%	New
Boxer Capital Management, LLC	275,000	$5.1M	0.4%	New
BlackRock, Inc.	240,679	$4.5M	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAROdyssey Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGAROdyssey Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARJason Haas, Chief financial officer
4
SEC EDGARAnthony W. Opipari, Officer
5
SEC EDGARCollin M. Todd, Officer
6
SEC EDGARGary D. Glick, Officer
7
SEC EDGARJolie Siegel, Officer
8
SEC EDGARNatalie Dales, Officer
9
SEC EDGARAranicki Ksenija Pavletic, Board member
10
SEC EDGARCarolyn Ng, Board member
11
SEC EDGARIan F. Smith, Board member
12
SEC EDGARJeffrey Leiden, Board member
13
SEC EDGAROurania Tatsis, Board member
14
SEC EDGARShelley Chu, Board member
15
SEC EDGARTimothy P. Walbert, Board member
16
SEC EDGARValerie Odegard, Board member